Bacterial resistance has become a worldwide concern after the emergence of metallo β-lactamases MBLs. They represent one of the major mechanisms of bacterial resistance against beta-lactam antibiotics. Among MBLs, New Delhi metallo-β-lactamase-1 NDM-1, the most prevalent type, is extremely efficient in inactivating nearly all-available antibiotics including last resort carbapenems. No inhibitors for NDM-1 are currently available in therapy, making the spread of NDM-1 producing bacterial strains a serious menace. In this perspective, we performed a structure-based in silico screening of a commercially available library using FLAPdock and identified several, non β-lactam derivatives as promising candidates active against NDM-1. The binding affinities of the highest scoring hits were measured in vitro revealing, for some of them, low micromolar affinity towards NDM-1. For the best inhibitors, efficacy against resistant bacterial strains overexpressing NDM-1 was validated, confirming their favorable synergistic effect in combination with the carbapenem Meropenem

Bacterial resistance has become a worldwide concern after the emergence of metallo-β-lactamases (MBLs). They represent one of the major mechanisms of bacterial resistance against beta-lactam antibiotics. Among MBLs, New Delhi metallo-β-lactamase-1 NDM-1, the most prevalent type, is extremely efficient in inactivating nearly all-available antibiotics including last resort carbapenems. No inhibitors for NDM-1 are currently available in therapy, making the spread of NDM-1 producing bacterial strains a serious menace. With this perspective, we performed a structure-based in silico screening of a commercially available library using FLAPdock and identified several, non-β-lactam derivatives as promising candidates active against NDM-1. The binding affinities of the highest scoring hits were measured in vitro revealing, for some of them, low micromolar affinity toward NDM-1. For the best inhibitors, efficacy against resistant bacterial strains overexpressing NDM-1 was validated, confirming their favorable synergistic effect in combination with the carbapenem Meropenem.

Structure-based virtual screening for the discovery of novel inhibitors of New Delhi Metallo-β-lactamase-1 / Spyrakis, Francesca; Celenza, Giuseppe; Marcoccia, Francesca; Santucci, Matteo; Cross, Simon; Bellio, Pierangelo; Cendron, Laura; Perilli, Mariagrazia; Tondi, Donatella. - In: ACS MEDICINAL CHEMISTRY LETTERS. - ISSN 1948-5875. - 9:1(2018), pp. 45-50. [10.1021/acsmedchemlett.7b00428]

Structure-based virtual screening for the discovery of novel inhibitors of New Delhi Metallo-β-lactamase-1

Spyrakis, Francesca
Software
;
Santucci, Matteo
Methodology
;
Tondi, Donatella
Supervision
2018-01-01

Abstract

Bacterial resistance has become a worldwide concern after the emergence of metallo β-lactamases MBLs. They represent one of the major mechanisms of bacterial resistance against beta-lactam antibiotics. Among MBLs, New Delhi metallo-β-lactamase-1 NDM-1, the most prevalent type, is extremely efficient in inactivating nearly all-available antibiotics including last resort carbapenems. No inhibitors for NDM-1 are currently available in therapy, making the spread of NDM-1 producing bacterial strains a serious menace. In this perspective, we performed a structure-based in silico screening of a commercially available library using FLAPdock and identified several, non β-lactam derivatives as promising candidates active against NDM-1. The binding affinities of the highest scoring hits were measured in vitro revealing, for some of them, low micromolar affinity towards NDM-1. For the best inhibitors, efficacy against resistant bacterial strains overexpressing NDM-1 was validated, confirming their favorable synergistic effect in combination with the carbapenem Meropenem
26-nov-2017
9
1
45
50
Structure-based virtual screening for the discovery of novel inhibitors of New Delhi Metallo-β-lactamase-1 / Spyrakis, Francesca; Celenza, Giuseppe; Marcoccia, Francesca; Santucci, Matteo; Cross, Simon; Bellio, Pierangelo; Cendron, Laura; Perilli, Mariagrazia; Tondi, Donatella. - In: ACS MEDICINAL CHEMISTRY LETTERS. - ISSN 1948-5875. - 9:1(2018), pp. 45-50. [10.1021/acsmedchemlett.7b00428]
Spyrakis, Francesca; Celenza, Giuseppe; Marcoccia, Francesca; Santucci, Matteo; Cross, Simon; Bellio, Pierangelo; Cendron, Laura; Perilli, Mariagrazia; Tondi, Donatella
File in questo prodotto:
File Dimensione Formato  
acsmedchemlett.7b00428.pdf

non disponibili

Tipologia: Versione pubblicata dall'editore
Dimensione 2.28 MB
Formato Adobe PDF
2.28 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1148690
Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 34
  • ???jsp.display-item.citation.isi??? 34
social impact